Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...

Here are key takeaways from latest research and a session of the European Association of the Study of Diabetes (EASD) ...

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new trials ...

Incretin therapies based on GLP-1 receptor agonism aid in the loss of weight in obesity, but a relevant part of this loss (25%-40%) is attributed to loss of lean muscle mass, which raises the risk of ...

We need to take stock of the promises and limitations of new “miracle” weight loss drugs and treat the cause of weight gain, ...

For too long, middlemen like pharmacy benefit managers have taken advantage of the complexity of the drug supply chain to ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

For years, the healthcare industry has been a cornerstone of the economy, offering resilience in both stable and uncertain ...

近日，首都医科大学附属北京同仁医院的杨金奎教授团队在《Signal Transduction and Targeted Therapy》发表了题为“Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies”的封面研究论文 ...

Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK ...